2024年美国临床肿瘤学会年会(American Society of Clinical Oncology,ASCO)将于5月31日至6月4日在美国芝加哥举行,荣昌生物(股票代码:688331.SH / 09995.HK)将携重磅研究成果再次登上这一顶尖国际学术舞台,唱响中国创新药好声音,展示开创性新治疗手段的“中国方案”。
在本次大会上,荣昌生物原创原研的我国首个获批上市的国产抗体偶联(ADC)药物维迪西妥单抗、靶向间皮素(MSLN)ADC药物RC88等两款创新药的16项最新临床研究数据,将精彩亮相,具体包括1项临床科学研讨、5项壁报展示、10项线上摘要,覆盖胃癌、膀胱癌、妇瘤等多个癌种,不仅有单药还有多种联合疗法。让我们抢先看看荣昌生物入选本届ASCO大会的“豪华阵容”!
1项临床科学研讨
Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS).
摘要编号:#4009
展示形式:临床科学研讨会
展示时间:6月2日下午4:30(美国东部时间)
第一作者:刘联教授 山东大学齐鲁医院
5项壁报展示
01
RC88在卵巢癌、非鳞状非小细胞肺癌和宫颈癌患者中的疗效和安全性:一项首次人体1/2期临床研究的结果
The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study.
摘要编号:#5551
壁报编号:#422
展示形式:壁报展示
展示时间:6月3日上午9:00(美国东部时间)
第一作者:刘雨桃教授 中国医学科学院肿瘤医院
02
RC48-C017的初步疗效和安全性结果:一项针对HER2表达的肌层浸润性膀胱癌(MIBC)患者使用维迪西妥单抗联合特瑞普利单抗进行新辅助治疗的II期研究
Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression.
摘要编号:#4568
壁报编号:#263
展示形式:壁报展示
展示时间:6月2日上午9:00(美国东部时间)
第一作者:盛锡楠教授 北京大学肿瘤医院
03
Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study.
摘要编号:#TPS4625
壁报编号:#311a
展示形式:壁报展示
展示时间:6月2日上午9:00(美国东部时间)
主要研究者:曾浩教授 四川大学华西医院
第一作者:陈俊儒教授 四川大学华西医院
04
评价维迪西妥单抗治疗HER2表达的2L复发或转移性宫颈癌(r/mCC)有效性和安全性:RC48-C018的中期结果
Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r/mCC): Interim results of RC48-C018.
摘要编号:#5528
壁报编号:#399
展示形式:壁报展示
展示时间:6月3日上午9:00(美国东部时间)
第一作者:袁光文教授 中国医学科学院肿瘤医院
05
一项前瞻性、单臂、单中心临床研究:维迪西妥单抗联合特瑞普利单抗治疗进展或对顺铂化疗不耐受的晚期阴茎癌患者
SAVE: A prospective, single-arm, single-center clinical study of disitamab vedotin in combination with toripalimab in patients with advanced penile cancer that has progressed or is intolerant to cisplatin chemotherapy.
摘要编号:#TPS5107
壁报编号:#513a
展示形式:壁报展示
展示时间:6月2日上午9:00(美国东部时间)
第一作者:袁方教授 重庆大学附属肿瘤医院
10项线上摘要
#e13011评价维迪西妥单抗在HER-2表达的乳腺癌中的疗效与安全性:一项多中心回顾性研究
Efficacy and safety of disitamab vedotin (RC48) in HER2-expressing breast cancer: A multicenter retrospective study
02
#e13022维迪西妥单抗(RC48)治疗HER2阳性晚期乳腺癌的有效性和安全性:来自中国的真实世界经验
Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.
03
#e12636重组人源化抗HER2抗体-MMAE结合物(RC48)用于HER2阳性乳腺癌新辅助治疗的有效性和安全性:一项单臂II期研究
Efficacy and safety of recombinant humanized anti-HER2 antibody-MMAE conjugate (RC48) in neoadjuvant for HER2-positive breast cancer: A single-arm phase II study.
04
#e15003维迪西妥单抗联合呋喹替尼治疗至少两种标准疗法难治的HER2表达或HER2突变/扩增的转移性结直肠癌患者:一项前瞻性、探索性、单臂研究
Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.
#e16590维迪西妥单抗联合特瑞普利单抗新辅助治疗肌层浸润性膀胱癌后选择性保膀胱或根治性膀胱切除术的有效性和安全性
Efficacy and safety of neoadjuvant therapy with disitamab vedotin plus toripalimab in treating muscle invasive urothelial bladder cancer followed by selective bladder-preserving or radical cystectomy.
06
#e16614 HER2过表达的膀胱癌(BC)的肿瘤免疫特征,以及对HER2过度表达的高风险非肌层浸润性BC的RC48-ADC对比卡介苗的研究
The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over-expression.
07
Preliminary results from a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).
08
#e16100维迪西妥单抗(RC48)联合卡瑞利珠单抗和S-1用于HER2过表达的局部晚期胃癌新辅助治疗的有效性和安全性:一项前瞻性单臂II期研究的初步结果
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study.
#e16572维迪西妥单抗(DV,RC48-ADC)联合卡度尼利单抗(抗PD-1/CTLA-4双特异性抗体)治疗局部晚期或转移性尿路上皮癌(la/mUC)患者:一项开放标签、单臂II期研究
Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study.
10
Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC).